Fresenius Medical Care AG (FMS) Stock Price

FMSStock

$22.17−15.15%52W

Market Cap$11.80B

P/E10.72x

PEG Ratio0.71

Div yield3.06%

Beta0.22

FMS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-9.98%

Price vs S&P 500 (4W)3.10%

PEG Ratio0.71

VGM Score55.14

P/E Ratio (Annual)10.72x

Indicated Dividend Yield (Annual)3.06%

P/CF (Annual)3.91x

Book Value / Share (Quarterly)$52.97

P/TBV (Annual)0.98x

Indicated Dividend (Annual)$1.67

Revenue Growth (3Y)0.39%

Cash Flow / Share (Quarterly)$7.47

Payout Ratio (TTM)183.24%

Price vs S&P 500 (YTD)-13.55%

Gross Margin (TTM)26.36%

Net Profit Margin (TTM)4.83%

EPS (TTM)$3.73

10-Day Avg Trading Volume1.08M

EPS Excl Extra (TTM)$3.73

Revenue Growth (5Y)1.91%

EPS (Annual)$3.77

Dividend / Share (Annual)$1.66

ROI (Annual)4.06%

Gross Margin (Annual)25.62%

Net Profit Margin (5Y Avg)3.86%

Cash / Share (Quarterly)$6.11

P/E Basic Excl Extra (TTM)11.18x

Revenue Growth QoQ (YoY)1.44%

EPS Growth (5Y)-3.23%

P/E Normalized (Annual)10.72x

ROA (Last FY)3.16%

Revenue Growth TTM (YoY)-0.46%

EBITD / Share (TTM)$13.53

ROE (5Y Avg)5.43%

Operating Margin (TTM)9.38%

Cash Flow / Share (Annual)$7.01

P/B Ratio0.83x

P/B Ratio (Quarterly)0.85x

Net Income / Employee (Annual)$9,990

EV / Revenue (TTM)1.05x

Net Interest Coverage (TTM)6.95x

ROA (TTM)3.01%

EPS Growth QoQ (YoY)5.95%

EV / EBITDA (TTM)6.03x

EPS Incl Extra (Annual)$3.77

Current Ratio (Annual)1.26x

Quick Ratio (Quarterly)0.75x

3-Month Avg Trading Volume0.85M

52-Week Price Return-15.15%

EV / Free Cash Flow (Annual)11.69x

P/E Incl Extra (TTM)11.18x

Revenue / Employee (TTM)$198,796

Tangible BV / Share (Quarterly)$47.57

P/S Ratio (Annual)0.53x

Asset Turnover (Annual)0.63x

52-Week High$53.36

Operating Margin (5Y Avg)8.37%

EPS Excl Extra (Annual)$3.77

CapEx CAGR (5Y)-2.89%

Tangible BV CAGR (5Y)4.16%

26-Week Price Return-0.08%

Quick Ratio (Annual)0.90x

13-Week Price Return-6.46%

Total Debt / Equity (Annual)0.81x

Current Ratio (Quarterly)1.07x

Enterprise Value$22.88B

Revenue / Share Growth (5Y)2.11%

Asset Turnover (TTM)0.62x

Book Value / Share Growth (5Y)4.47%

Revenue / Employee (Annual)$200,817

Inventory Turnover (Annual)6.94x

Pretax Margin (Annual)7.70%

Cash / Share (Annual)$7.44

3-Month Return Std Dev27.99%

Gross Margin (5Y Avg)25.57%

Net Income / Employee (TTM)$9,541

EBITDA CAGR (5Y)7.58%

EBITDA Interim CAGR (5Y)14.27%

ROE (Last FY)7.35%

Net Interest Coverage (Annual)6.43x

EPS Basic Excl Extra (Annual)$3.77

P/FCF (TTM)5.92x

Receivables Turnover (TTM)5.94x

EV / Free Cash Flow (TTM)11.51x

Total Debt / Equity (Quarterly)0.87x

EPS Incl Extra (TTM)$3.73

Receivables Turnover (Annual)6.03x

ROI (TTM)3.94%

Dividend Growth Rate (5Y)4.43%

P/S Ratio (TTM)0.54x

Pretax Margin (5Y Avg)6.74%

Revenue / Share (Annual)$75.66

Tangible BV / Share (Annual)$48.45

Forward P/E9.38x

Free OCF CAGR (5Y)-11.14%

Price vs S&P 500 (52W)-30.68%

P/E Ratio (TTM)11.18x

EPS Growth TTM (YoY)48.65%

Year-to-Date Return-2.99%

5-Day Price Return4.33%

EPS Normalized (Annual)$3.77

ROA (5Y Avg)2.19%

Net Profit Margin (Annual)4.98%

Month-to-Date Return-0.08%

Cash Flow / Share (TTM)$8.76

EBITD / Share (Annual)$12.83

EPS Growth (3Y)13.53%

Operating Margin (Annual)9.31%

LT Debt / Equity (Annual)0.43x

P/CF (TTM)3.70x

ROI (5Y Avg)2.86%

P/E Excl Extra (TTM)11.18x

LT Debt / Equity (Quarterly)0.46x

EPS Basic Excl Extra (TTM)$3.73

P/TBV (Quarterly)0.94x

Payout Ratio (Annual)43.19%

P/B Ratio (Annual)0.89x

Dividend / Share (TTM)$1.61

Inventory Turnover (TTM)6.61x

Pretax Margin (TTM)7.73%

Book Value / Share (Annual)$53.49

Price vs S&P 500 (13W)-9.14%

Net Margin Growth (5Y)-5.25%

Dividend Yield (TTM)3.82%

Beta0.22x

P/FCF (Annual)6.01x

Revenue / Share (TTM)$81.24

ROE (TTM)7.21%

52-Week Low$38.81

vGradeA

gGradeD

mGradeC

vgmGradeC

FMS Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 3, 2026	$0.56	$0.63	+13.11%(+$0.08)
Q1 2026	May 4, 2026	$0.56	$0.51	-8.63%(-$0.04)
Q4 2025	Feb 24, 2026	$0.62	$0.81	+29.96%(+$0.19)
Q3 2025	Nov 4, 2025	$0.57	$0.62	+9.13%(+$0.06)
Q2 2025	Aug 5, 2025	$0.52	$0.51	-2.36%(-$0.01)

FMS Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

3.31

2.89

2.86

2.83

Industry Peers — Health Services(17)

Symbol	Value Score	Growth Score	Momentum Score	P/E Ratio (Annual)	Revenue Growth TTM (YoY)	Operating Margin (TTM)	ROE (TTM)	Price
FMSFresenius Medical Care AG	A	D	C	10.7x	-0.5%	9.4%	7.2%	$22.17
DVADaVita Inc.	B	C	B	16.0x	6.5%	15.1%	181.2%	$187.31
SHCSotera Health Company Common Stock	D	B	C	65.5x	8.2%	32.6%	26.8%	$17.89
PGNYProgyny, Inc. Common Stock	C	B	C	35.2x	5.5%	8.6%	16.0%	$26.86
AGLagilon health, inc.	B	B	B	—	0.3%	-5.2%	-110.3%	$85.12
MCTACharming Medical Limited Class A Ordinary Shares	F	F	A	371.6x	—	15.4%	—	$29.36
VMDViemed Healthcare, Inc. Common Shares	B	C	C	24.2x	25.2%	7.5%	10.3%	$9.48
PARKPark Dental Partners, Inc. Common Stock	B	F	C	17.9x	—	-2.8%	-18.3%	$18.95
CCELCryo-Cell International Inc.	C	D	B	69.5x	-2.0%	0.6%	38.2%	$4.42
MGRXMangoceuticals, Inc. Common Stock	D	F	F	—	-38.9%	-4761.2%	-106.1%	$0.29
BRTXBioRestorative Therapies, Inc. Common Stock (NV)	—	D	F	—	-8.5%	-3975.0%	-423.8%	$1.54
NIVFNewGenIvf Group Limited Class A ordinary shares	A	C	F	0.3x	—	390.2%	45.4%	$0.28
NIVFWNewGenIvf Group Limited Warrants	—	—	D	—	—	—	—	$0.01
OAKUOak Woods Acquisition Corporation Class A Ordinary Shares	—	F	B	174.5x	—	—	-0.6%	$0.00
OAKUROak Woods Acquisition Corporation Right	—	F	B	174.5x	—	—	-0.6%	$0.00
OAKUUOak Woods Acquisition Corporation Unit	—	F	B	174.5x	—	—	-0.6%	$0.00
OAKUWOak Woods Acquisition Corporation Warrant	—	—	F	—	—	—	—	$0.00
QIPTQuipt Home Medical Corp. Ordinary Shares	B	B	B	—	9.5%	-1.2%	-10.5%	$0.00

About Fresenius Medical Care AG

Fresenius Medical Care is the world's largest dialysis provider, operating approximately 3,600 clinics treating nearly 300,000 patients globally. As the only fully integrated dialysis business, it controls roughly 35% of the global dialysis products market through supplies of machines, dialyzers, and concentrates. The company generates approximately 75% of revenue from services and 25% from dialysis products, creating a diversified business model with competitive advantages in both treatment delivery and product supply.